What is Liquid Biopsy?  

    Cancer detection and monitoring method

    Liquid Biopsy, also known as fluid biopsy, is a significant branch of in vitro diagnosis that is primarily based on blood or other body fluid for disease analysis and monitoring, such as cancer. With a simple blood draw, circulating tumor biomarkers in the blood sample provide information on tumor progression and treatment efficacy, and guiding personalized precision medication direction. Compared with traditional tissue biopsy, liquid biopsy has provided additional benefits of real-time monitoring, avoid unrepresentative sampling in heterogenous tumor, and provides comprehensive clinical information.

    Liquid Biopsy is a branch of in vitro diagnostics that analyses and diagnoses diseases such as cancer through the use of body liquids like blood or urine. It was rated as one of the “Breakthrough Technologies 2015” by MIT Technology Review.

    Compared to traditional tissue biopsy, liquid biopsy is equipped with unique advantages like real-time monitoring, ability to overcome tumor heterogeneity, and comprehensive diagnostic information. Currently, in clinical researches, liquid biosy mainly includes tests for CTC (Circulating Tumor Cell), ctDNA (Circulating Tumor DNA), exosomes, and Circulating miRNA etc. In comparison to traditional methods like observation of clinical symptoms or diagnostic imaging, using liquid biopsy can predict the risk of cancer earlier, enabling “Early discovery, early screening, early treatment”.

What is Circulating miRNA?

microRNAs or miRNAs are small RNA molecules that are non-coding and have important effects on gene expression, often inhibitory.  By binding to mRNAs in the cells, the microRNAs inhibit DNA functioning, thus affecting important life functions in a cell. In many cancer types, miRNAs production is upregulated, converting an ordinary cell into a cancerous one. Additionally, these miRNAs can be transported outside the cell, in the tumour environment, in sacs/vesicles called 'exosomes'. The presence of a high number of exosomal miRNAs has been associated with the spread of certain types of cancer in the body. Isolation and detection of miRNAs from a patient’s blood can help in early cancer diagnosis, without the need for invasive surgeries.

What is Circulating Tumor Cell (CTC)?

Circulating tumor cell (CTCs) are the cancer cells that have detached from the primary tumor or metastatic tumor into circulatory system during tumor progression or metastases. CTC provides comprehensive information of cancer in cellular, genetics and protein levels. Hence, CTC detection is an effective tool for earlier detection, evaluation of therapeutic efficacy, individual precision medicine selection, drug resistance detection, earlier tumor recurrence evaluation and real-time monitoring of cancer.

How can we detect CTCs in blood?

Cellomics CTC detection Platform - New generation of CTC viable Cell Sorting.

The CTC detection platform has employed the leading microfluidic chip technology that select CTCs extensively by cell size, cell shape and multiple surface biomarkers. This technology has combined the physical, chemical and biological properties of CTCs to uphold the high sensitivity, high specificity and high accuracy of CTC detection.




Company Overview

 Live Now & The Future Direction

We are dedicated to providing high-efficiency and accurate individualized liquid biopsy products and services for cancer patients. We independently and fully own the intellectual property rights to advanced microfluidic chip technology and nucleic acid detection technology, which we utilize to provide comprehensive, high-precision, high-throughput and low-cost tumor liquid biopsy diagnostic solutions, services and products, including circulating tumor cell sorting chips and device, droplet digital PCR chips and devices, ctDNA and miRNA detection kit products for tumor liquid biopsy, etc. 

Cellomics also operates a "Medical Laboratory" and "CTC detection Laboratory". We have become a comprehensive service platform integrating clinical testing services, scientific research and development. We are committed to providing precise detection and personalized drug guidance technical services, and aim to be a key partner of clinical medical units and scientific research institutions, benefiting the large number of patients suffering from chronic diseases such as cancer, cardiovascular disease and diabetes.

Our future development / pipeline projects will combine with the latest international academic research to extend our products / services range to include the precise treatment and monitoring of a variety of major high-incidence chronic diseases.

Leader Ship
Scientific Advisors
Board of Directors
Key Investment Highlights

Key Investment Highlights

Clear near-term exit with potential HK IPO commanding high valuation

Best in class technology and team


Industry Potential

Potential paradigm shift in existing cancer diagnostic and treatment modality, presenting a multi-billion-dollar global market opportunity .
Best in class technology and team
Cellomics is the frontrunner in liquid biopsy for cancer diagnosis with strong proprietary IP & technologies, with the largest dataset derived from large-scale population and long term follow-up clinical studies .

Advantage Resource

Cellomics well-funded and backed by the world’s large pharmaceutical and healthcare corporations and investors .Cellomics’strong partnerships/collaborations with healthcare institutions enable clinical validation and partnership with healthcare insurers allows rapid commercialization .



CTC 100 Sorter





The Team




Contact Us

Email: info@cellomicsbio.com

Tel: +86-0755-28378001

Copyright © 2020 Cellomics All Rights Reserved

Copyright © 2020 Cellomics All Rights Reserved